Downregulation of proinflammatory cytokine release in whole blood from septic patients

Blood

Volumn 85, Issue 5, 1995, Pages 1341-1347

  Ertel, Wolfgang ^a   Kremer, Jean Pierre ^b   Kenney, John ^b   Steckholzer, Ursula ^b   Jarrar, Doraid ^b   Trentz, Otmar ^b   Schildberg, Friedrich Wilhelm ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 6;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SEPSIS;

EID: 0028937425     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v85.5.1341.bloodjournal8551341     Document Type: Article

References (69)

1. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481, 1988
2. Van Zee KJ, DeForge LE, Fischer E, Marano MA, Kenney JS, Remick DG, Lowry SF, Moldawer LL: IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 146:3478, 1991
3. Martich DG, Danner RL, Ceska M, Suffredini AF: Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of antiinflammatory agents. J Exp Med 173:1021, 1991
4. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey III TJ, Zentella A, Albert JD, Shires GT, Cerami A: Shock and tissue injury induced by recombinant human cachectin. Science 234:470, 1986
5. Tracey KJ, Lowry SF, Fahey III TJ, Albert JD, Fong Y, Hesse D, Beutler B. Manogue KR, Calvano S, Wei H, Cerami A, Shires GT: Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet 164:415, 1987
6. Beutler B, Cerami A: The biology of cachectin/TNF - primary mediator of host response. Annu Rev Immunol 7:625, 1989
7. Okusawa S, Gelfand A, Ikejima T, Connolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162, 1988
8. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627, 1991
9. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869, 1985
10. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662, 1987
11. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock. J Infect Dis 162:421, 1990
12. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550, 1990
13. Beutler BA, Milsark IW, Cerami A: Cachectin/tumor necrosis factor: Production, distribution, and metabolic fate in vivo. J Immunol 135:3972, 1985
14. Klapproth J, Castell JV, Geiger T, Andus T, Heinrich PC: Fate and biological action of human recombinant interleukin 1β in the rat in vivo. Eur J Immunol 19:1485, 1989
15. Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC: Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 177:357, 1988
16. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, J5 Study Group, Lambert PH: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319:397, 1988
17. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, Van Der Meer JWM, Endres S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW, Wolff SM, Burke JF, Dinarello CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79, 1990
18. Marks JD, Berman-Marks C, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF: Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 141:94, 1990
19. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/ cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis 161:982, 1990
20. Debets JMH, Kampmeijer R, Van Der Linden MPM, Buurman WA, Van Der Linden CJ: Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489, 1989
21. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975, 1989
22. Haskill S, Johnson C, Eierman D, Becker S, Warren K: Adherence induces selective mRNA expression of monocyte mediators and protooncogenes. J Immunol 140:1690, 1988
23. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA. Balk RA: Methylprednisolone severe sepsis study group: Sepsis syndrome: A valid clinical entity. Crit Care Med 17:389, 1989
24. Van Deventer SJH, Büller HR, ten Cate JW, Sturck A, Pauw W: Endotoxemia: An early predictor of septicemia in febrile patients. Lancet 1:605, 1988
25. Shenep JL, Flynn PM, Barrett FF, Stidham GL, Westenkirchner DF: Serial quantitation of endotoxemia and bacteremia during therapy for gram-negative bacterial sepsis. J Infect Dis 157:565, 1988
26. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99, 1986
27. Eskandari MK, Nguyen DT, Kunkel SL, Remick DG: WEHI 164 suclone 13 assay for TNF: Sensitivity, specificity, and reliability. Immunol Invest 19:69, 1990
28. 2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas. Proc Natl Acad Sci USA 83:9679, 1989
29. Ertel W, Morrison MH, Ayala A, Chaudry IH: Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood 78:1781, 1991
30. Larrick JW: Native interleukin 1 inhibitors. Immunol Today 10:61, 1989
31. Cannon JG, Van Der Meer JWM, Kwiatkowski D, Endres S, Lonnemann G, Burke JF, Dinarello CA: Interleukin-1β in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7:457, 1988
32. Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins MA, Allison AC: Monoclonal antibodies to human recombinant interleukin 1 (IL-1β): Quantitation of IL-1β and inhibition of biological activity. J Immunol 138:4236, 1987
33. Chromczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
34. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
35. Kremer JP, Reisbach G, Nerl C, Dörmer P: B-cell chronic lymphocytic leukemia cells express and release transforming growth factor-β. Brit J Haematol 80:480, 1992
36. DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG: Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. J Immunol 148:2133, 1992
37. DeForge LE, Nguyen DT, Kunkel SL, Remick DG: Regulation of the pathophysiology of tumor necrosis factor. J Lab Clin Med 116:429, 1990
38. Ertel W, Morrison MH, Ayala A, Perrin MM, Chaudry IH: Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions after hemorrhagic shock. Ann Surg 213:265, 1991
39. Ertel W, Morrison MH, Ayala A, Chaudry IH: Eicosanoids regulate tumor necrosis factor synthesis after hemorrhage in vitro and in vivo. J Trauma 31:609, 1991
40. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431, 1990
41. Knudsen PJ, Dinarello CA, Strom TB: Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol 137:3189, 1986
42. Schindler R, Clark BD, Dinarello CA: Dissociation between interleukin-1β mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 265:10232, 1990
43. Zuckerman SH, Evans GF, Butler LD: Endotoxin tolerance: Independent regulation of interleukin-1 and tumor necrosis factor expression. Infect Immun 59:2774, 1991
44. Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129, 1987
45. 2 in immune suppression following injury. Ann Surg 214:253, 1991
46. Farmer TA, Hill SR, Pittman JA, Herod JW: The plasma 17-hydroxycorticosteroid response to corticothrophin, SU-4885 and lipopolysaccharide pyrogen. J Clin Endocrinol Metab 21:433, 1961
47. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem 263:5380, 1988
48. Remick DG, Strieter RM, Lynch JP, Nguyen D, Eskandari M, Kunkel SL: In vivo dynamics of murine tumor necrosis factoralpha gene expression: Kinetics of dexamethasone-induced suppression. Lab Invest 60:766, 1989
49. Esser R, Rhoades K, McBride WH, Morton DL, Economou JS: IL-4 downregulates IL-1 and TNF gene expression in human monocytes. J Immunol 142:3857, 1989
50. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209, 1991
51. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kagad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362:248, 1993
52. Bogdan C, Paik J, Vodovotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 267:23301, 1992
53. Ertel W, Scholl FA, Gallati H, Bonaccio M, Schildberg FW, Trentz O: Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg 129:1330, 1994
54. Ertel W, Karres I, Kremer JP, Kenney JS, Faist E, Schildberg FW: Transforming growth factor type β1 (TGF-β1) is a strong anti-inflammatory cytokine that inhibits transcription, translation, and secretion of inflammatory mediators on different levels. Surg Forum 44:105, 1993
55. Ayala A, Knotts JK, Ertel W, Perrin MM, Morrison MH, Chaudry IH: Role of interleukin 6 and transforming growth factor-β in the induction of depressed splenocyte responses following sepsis. Arch Surg 128:89, 1993
56. Fahmi H, Chaby R. Desensitization of macrophages to endotoxin effects is not correlated with a down-regulation of lipopolysaccharide-binding sites. Cell Immunol 150:219, 1993
57. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA: Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151:1637, 1993
58. Rodrick ML, Moss NM, Grbic JT, Revhaug A, O'Dwyer ST, Michie HR, Gough DB, Dubravec D, Manson JM, Saporoschetz IB, Collins KH, Jordan AL, Wilmore DW, Mannick JA: Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans. J Clin Immunol 12:440, 1992
59. Rock CS, Lowry SF: Tumor necrosis factor-α. J Surg Res 51:434, 1991
60. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis 163:1177, 1991
61. Jelinek DF, Lipsky PE: Enhancement of human B-cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol 139:2970, 1987
62. Zucali JR, Elfenbein GJ, Barth KC, Dinarello CA: Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest 80:772, 1987
63. Chang RJ, Lee SH: Effects of interferon-μ and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line. J Immunol 137:2853, 1986
64. Esparza I, Mannel D, Ruppel A, Falk W, Krammer P: Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med 166:589, 1987
65. Scuderi P, Sterling KE, Lam KS, Finley PR, Ryan KJ, Ray CG, Petersen E, Slymen DS, Salomon SE: Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1364, 1986
66. Czuprynski CJ, Brown JF: Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect Immun 55:2061, 1987
67. Sheppard BC, Fraker DL, Norton JA: Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 106:156, 1989
68. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P: Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin-1α protects mice from lethal bacterial infection. J Exp Med 169:2021, 1989
69. Alexander HR, Doherty GM, Block MI, Kragel PJ, Jensen JC, Langstein HN, Walker E, Norton JA: Single-dose tumor necrosis factor protection against endotoxin-induced shock and tissue injury in rats. Infect Immun 59:3889, 1991